CymaBay Therapeutics

147 articles about CymaBay Therapeutics

• CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

  11/16/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced an oral late-breaking presentation of the positive results from the ENHANCE phase 3 study evaluating seladelpar for primary biliary cholangitis (PBC).

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Nov 11, 2020

  11/11/2020

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including Stifel 2020 Virtual Healthcare Conference taking place November 16-19, 2020, the Evercore ISI 3rd Annual HealthCONx Conference taking place December 1-3, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1- 3, 2020.

• 

  Clinical Catch-Up: November 2-6

  11/9/2020

  It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.

• CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  CymaBay announces trial design for RESPONSE, a global phase 3 registration study for seladelpar in primary biliary cholangitis (PBC)

• CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes

  11/5/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it will provide its proprietary investigational GPR119 agonist, MBX-2982, and will assist in regulatory filings for a clinical study to be conducted by the TRI

• CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

  11/2/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be delivered during The Liver Meeting Digital Experience™ 2020 (TLMdX)

• CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

  10/30/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.

• CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020

  10/1/2020

  CymaBay Therapeutics, Inc. announced that data from a Phase 2 study of seladelpar in nonalcoholic steatohepatitis will be delivered during The Liver Meeting Digital Experience™ 2020 of the American Association for the Study of Liver Diseases which will be held online November 13th – 16th.

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Sep 03, 2020

  9/3/2020

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including Citi’s 15th Annual BioPharma Conference taking place September 9-10, 2020, the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14-16, 2020 and the Cantor Global Healthcare Conference taking place September 15-17, 2020.

• CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020

  8/27/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC).

• CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020A featured presentation will highlight final results from a 1-year, open-label Phase 2 study of seladelpar in primary biliary cholangitis (PBC)

  8/20/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress™ 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27 th – 29 th . The presentation titled “D

• CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/10/2020

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the second quarter and six months ended June 30, 2020.

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
• 

  CymaBay Therapeutics' PBC Treatment Hits the Mark in Phase III Study

  8/3/2020

  Shares of CymaBay Therapeutics soared after the company announced its experimental primary biliary cholangitis (PBC) treatment seladelpar hit the mark in a Phase III study that sets up potential regulatory approval for this indication.

• CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

  8/3/2020

  CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter and six months ended June 30, 2020 and to provide a business update.

• CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis

  8/3/2020

  CymaBay Therapeutics, Inc. announced positive topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis.

• 

  Clinical Catch-Up: July 20-24

  7/27/2020

  It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

• FDA Lifts All Clinical Holds on Seladelpar

  7/23/2020

  Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC  Re-initiating clinical development focusing first on Phase 3 for PBC

• CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education

  6/19/2020

  Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also observed NEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously compl

• Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

  6/5/2020

  CymaBay Therapeutics, Inc. (Nasdaq: CBAY),  today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others,